6-K 1 ea023570201-6k_ascentage.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of March 2025

 

Commission File Number: 001-42484

 

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

 

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

 

 

 

 

On March 25, 2025, Ascentage Pharma Group International issued a press release entitled “ASCENTAGE PHARMA TO PRESENT FIVE PRECLINICAL STUDIES FROM INNOVATIVE PIPELINE AT AMERICAN ASSOCIATION OF CANCER RESEARCH (AACR) ANNUAL MEETING 2025”.

 

A copy of the press release is attached as Exhibit 99.1 to this Form 6-K and is incorporated by reference herein.

 

1

 

 

INDEX TO EXHIBITS

Exhibit  
Number Exhibit Title
       
99.1  

Press Release dated March 25, 2025

  

 

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

    ASCENTAGE PHARMA GROUP INTERNATIONAL
     
Date: March 25, 2025   /s/ Dajun Yang
    Name: Dajun Yang
    Title:   Chief Executive Officer

 

 

3